The DOI matches its Crossref record; 71 of the 71 references it cites were found in a registry or an index.
Caffeine protects against MPTP‐induced blood‐brain barrier dysfunction in mouse striatum
Open accessAbstract
The blood‐brain barrier (BBB) is important physiologically. Pathologically, BBB disruption has been implicated in a wide spectrum of neurological disorders including Parkinson’s disease (PD). Recent studies indicate that caffeine is protective against PD, but by poorly understood mechanisms. Using a MPTP neurotoxin model of PD we tested the hypothesis that the protective actions of caffeine were because of, at least in part, preventing MPTP‐induced BBB dysfunction. FVB mice were pre‐treated with caffeine (10 mg/kg, i.p.) or saline for 7 days prior to initiation of neurotoxin treatments; during the 7 days of neurotoxin treatment, caffeine or saline continued to be administered 10 min before each dose of MPTP (20 mg/kg, i.p.). Striatum (and for some studies hippocampus and cerebral cortex as well) were evaluated for BBB leakage, tight junction protein expression levels, integrity of dopaminergic neurons, and activation of astrocytes and microglia using immunostaining, immunoblotting and real‐time PCR techniques. We found that caffeine blocked MPTP‐induced decreases in numbers of tyrosine hydroxylase‐positive dopaminergic neurons, increases in leakage of Evan’s blue dye and FITC‐albumin in striatum but not in cerebral cortex or hippocampus, decreases in levels of the tight junction proteins occludin and ZO‐1, and increases in reactive gliosis. Our results suggest that caffeine might protect against PD and PD‐like features in animal models, in part, by stabilizing the BBB.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Reduced expression of TJ proteins has also been shown in MPTP PD models (108).”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [108]
The cited source says what the claim attributes to it.
In the citing paper
“compromised BBB integrity is also observed in rodent models of PD induced by systemic administration of MPTP (108, 680) or intrastriatal administration of 6-hydroxydopamine (6-OHDA) (95), including leakage of fluoresceinisothiocyanate (FITC)-labeled albumin (95, 108, 680), horseradish peroxidase (95), and Evan's blue (108) in the substantia nigra and striatum.”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [108]
In the citing paper
“nigrostriatal vascular leakage has been reported in MPTP-treated mice [73]”
From Healthy Human Fecal Microbiota Transplantation into Mice Attenuates MPTP-Induced Neurotoxicity via AMPK/SOD2 Pathway (2023) · cites this paper as [73]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Astrocyte-endothelial interactions at the blood-brain barrier
Abbott, N. J., Rönnbäck, L., & Hansson, E. (2006) · Nature Reviews Neuroscience · doi:10.1038/nrn1824 · Cited by 5,595
The Blood-Brain Barrier in Health and Chronic Neurodegenerative Disorders
Zlokovic, B. V. (2008) · Neuron · doi:10.1016/j.neuron.2008.01.003 · Cited by 3,280
McGeer, P. L., Itagaki, S., Boyes, B. E., & McGeer, E. G. (1988) · Neurology · doi:10.1212/wnl.38.8.1285 · Cited by 2,990
The blood-brain barrier/neurovascular unit in health and disease
Hawkins, B. T., & Davis, T. P. (2005) · Pharmacological Reviews · doi:10.1124/pr.57.2.4 · Cited by 2,661
Fredholm, B. B., Bättig, K., Holmén, J., Nehlig, A., & Zvartau, E. E. (1999) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01396-6 · Cited by 2,624
Nehlig, A., Daval, J., & Debry, G. (1992) · Brain Research Reviews · doi:10.1016/0165-0173(92)90012-b · Cited by 1,463
Lindsay, J. (2002) · American Journal of Epidemiology · doi:10.1093/aje/kwf074 · Cited by 1,261
In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease
Gerhard, A., Pavese, N., Hotton, G., Turkheimer, F., Es, M., Hammers, A., Eggert, K., Oertel, W., Banati, R. B., & Brooks, D. J. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2005.08.002 · Cited by 1,200
Coffee and Health: A Review of Recent Human Research
Higdon, J. V., & Frei, B. (2006) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408390500400009 · Cited by 1,090
Liberatore, G. T., Jackson-Lewis, V., Vukosavic, S., Mandir, A. S., Vila, M., McAuliffe, W. G., Dawson, V. L., Dawson, T. M., & Przedborski, S. (1999) · Nature Medicine · doi:10.1038/70978 · Cited by 1,046
Asahi, M., Wang, X., Mori, T., Sumii, T., Jung, J.-C., Moskowitz, M. A., Fini, M. E., & Lo, E. H. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-19-07724.2001 · Cited by 1,004
Pathophysiology of the basal ganglia in Parkinson's disease
Obeso, J. A., Rodríguez-Oroz, M. C., Rodrı́guez, M., Lanciego, J. L., Artieda, J., Gonzalo, N., & Olanow, C. W. (2000) · Trends in Neurosciences · doi:10.1016/s1471-1931(00)00028-8 · Cited by 874
Microglial activation and dopamine terminal loss in early Parkinson's disease
Ouchi, Y., Yoshikawa, E., Sekine, Y., Futatsubashi, M., Kanno, T., Ogusu, T., & Torizuka, T. (2005) · Annals of Neurology · doi:10.1002/ana.20338 · Cited by 869
Inflammatory Mediators and Modulation of Blood–Brain Barrier Permeability
Abbott, N. J. (2000) · Cellular and Molecular Neurobiology · doi:10.1023/a:1007074420772 · Cited by 803
Association of coffee and caffeine intake with the risk of Parkinson disease
Ross, G. W. (2000) · JAMA · doi:10.1001/jama.283.20.2674 · Cited by 778
A cell culture model of the blood-brain barrier.
Rubin, L. L., Hall, D. E., Porter, S., Barbu, K., Cannon, C., Horner, H. C., Janatpour, M. J., Liaw, C. W., Manning, K., & Morales, J. (1991) · The Journal of Cell Biology · doi:10.1083/jcb.115.6.1725 · Cited by 765
Blood–brain barrier dysfunction in parkinsonian midbrain in vivo
Kortekaas, R., Leenders, K. L., van Oostrom, J. C. H., Vaalburg, W., Bart, J., Willemsen, A. T. M., & Hendrikse, N. H. (2005) · Annals of Neurology · doi:10.1002/ana.20369 · Cited by 733
Role of matrix metalloproteinases in delayed cortical responses after stroke
Zhao, B., Wang, S. Y., Kim, H.-Y., Storrie, H., Rosen, B. R., Mooney, D. J., Wang, X., & Lo, E. H. (2006) · Nature Medicine · doi:10.1038/nm1387 · Cited by 704
Glial reactions in Parkinson's disease
McGeer, P. L., & McGeer, E. G. (2008) · Movement Disorders · doi:10.1002/mds.21751 · Cited by 701
Antonetti, D. A., Barber, A. J., Hollinger, L. A., Wolpert, E. B., & Gardner, T. W. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.33.23463 · Cited by 685
Blood-brain barrier disruption in multiple sclerosis
Minagar, A., & Alexander, J. S. (2003) · Multiple Sclerosis · doi:10.1191/1352458503ms965oa · Cited by 685
Prospective Study of Caffeine Consumption and Risk of Parkinson’s Disease in Men and Women
Ascherio, A., Zhang, S. M., Hernán, M. A., Kawachi, I., Colditz, G. A., Speizer, F. E., & Willett, W. C. (2001) · Annals of Neurology · doi:10.1002/ana.1052 · Cited by 677
Chen, J., Xu, K., Petzer, J. P., Staal, R. G. W., Xu, Y., Beilstein, M. A., Sonsalla, P. K., Castagnoli, K., Castagnoli, N. J., & Schwarzschild, M. A. (2001) · Journal of Neuroscience · doi:10.1523/jneurosci.21-10-j0001.2001 · Cited by 617
Possible Involvement of Phosphorylation of Occludin in Tight Junction Formation
Sakakibara, A., Furuse, M., Saitou, M., Ando‐Akatsuka, Y., & Tsukita, S. (1997) · The Journal of Cell Biology · doi:10.1083/jcb.137.6.1393 · Cited by 590
Microvascular injury and blood–brain barrier leakage in Alzheimer's disease
Zipser, B. D., Johanson, C. E., Gonzalez, L., Berzin, T. M., Tavares, R., Hulette, C. M., Vitek, M. P., Hovanesian, V., & Stopa, E. G. (2007) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2006.05.016 · Cited by 487
Arendash, G. W., Schleif, W. S., Rezai-Zadeh, K. P., Jackson, E. K., Zacharia, L. C., Cracchiolo, J. R., Shippy, D. C., & Tan, J. (2006) · Neuroscience · doi:10.1016/j.neuroscience.2006.07.021 · Cited by 476
Structural and functional aspects of the blood-brain barrier
Begley, D. J., & Brightman, M. (2003) · Birkhäuser Basel eBooks · doi:10.1007/978-3-0348-8049-7_2 · Cited by 474
Neuroinflammatory processes in Parkinson's disease
Hunot, S., & Hirsch, É. C. (2003) · Annals of Neurology · doi:10.1002/ana.10481 · Cited by 407
Kurkowska‐Jastrzębska, I., Wrońska, A., Kohutnicka, M., Członkowski, A., & Członkowska, A. (1999) · Experimental Neurology · doi:10.1006/exnr.1998.6993 · Cited by 379
Junctional complexes of the blood–brain barrier: permeability changes in neuroinflammation
Petty, M. A., & Lo, E. H. (2002) · Progress in Neurobiology · doi:10.1016/s0301-0082(02)00128-4 · Cited by 361
Does caffeine intake protect from Alzheimer's disease?
Maia, L., & de Mendonça, A. (2002) · European Journal of Neurology · doi:10.1046/j.1468-1331.2002.00421.x · Cited by 361
Blood—Brain Barrier Permeability Precedes Senile Plaque Formation in an Alzheimer Disease Model
UJIIE, M., DICKSTEIN, D. L., CARLOW, D. A., & JEFFERIES, W. A. (2003) · Microcirculation · doi:10.1038/sj.mn.7800212 · Cited by 351
The neuroprotective effects of caffeine: A prospective population study (the Three City Study)
Ritchie, K., Carrière, I., de Mendonça, A., Portet, F., Dartigues, J. F., Rouaud, O., Barberger-Gateau, P., & Ancelin, M. L. (2007) · Neurology · doi:10.1212/01.wnl.0000266670.35219.0c · Cited by 347
Blood–Brain Barrier Pathology in Alzheimer's and Parkinson's Disease: Implications for Drug Therapy
Desai, B. S., Monahan, A. J., Carvey, P. M., & Hendey, B. (2007) · Cell Transplantation · doi:10.3727/000000007783464731 · Cited by 339
Pflugfelder, S. C., Farley, W. J., Luo, L., Chen, L. Z., de Paiva, C. S., de Koo, L. C. O., Li, D., & Fini, M. E. (2005) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)62232-8 · Cited by 332
Neuroinflammatory processes in Parkinson's disease
Hirsch, É. C., Hunot, S., & Hartmann, A. (2005) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2004.10.013 · Cited by 303
Kohutnicka, M., Lewandowska, E., Kurkowska‐Jastrzębska, I., Członkowski, A., & Członkowska, A. (1998) · Immunopharmacology · doi:10.1016/s0162-3109(98)00022-8 · Cited by 283
Petito, C. K., & Cash, K. S. (1992) · Annals of Neurology · doi:10.1002/ana.410320509 · Cited by 276
López‐García, E., van Dam, R. M., Qi, L., & Hu, F. B. (2006) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/84.4.888 · Cited by 257
Neuroprotection by caffeine and adenosine A 2A receptor blockade of β ‐amyloid neurotoxicity
Dall'lgna, O. P., Porciúncula, L. O., Souza, D. O., Cunha, R. A., & Lara, D. R. (2003) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0705185 · Cited by 255
Immunomodulatory effects of caffeine: Friend or foe?
Horrigan, L. A., KELLY, J., & Connor, T. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2006.02.002 · Cited by 238
Smoking, alcohol, and coffee consumption preceding Parkinson’s disease: A case-control study
Benedetti, M. D., Bower, J. H., Maraganore, D. M., McDonnell, S. K., Peterson, B. J., Ahlskog, J. E., Schaid, D. J., & Rocca, W. A. (2000) · Neurology · doi:10.1212/wnl.55.9.1350 · Cited by 234
Chapter 36: Astrocytes and Parkinson's disease
Forno, L. S., DeLanney, L. E., Irwin, I., Monte, D. A. D., & Langston, J. W. (1992) · Progress in brain research · doi:10.1016/s0079-6123(08)61770-7 · Cited by 230
6-Hydroxydopamine-induced alterations in blood-brain barrier permeability
Carvey, P. M., Zhao, C. H., Hendey, B., Lum, H., Trachtenberg, J., Desai, B. S., Snyder, J., Zhu, Y. G., & Ling, Z. D. (2005) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2005.04281.x · Cited by 218
Adenosine receptor signaling in the brain immune system
Haskó, G., Pacher, P., Vizi, E. S., & Illés, P. (2005) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2005.08.004 · Cited by 214
Ishizaki, T., Chiba, H., Kojima, T., Fujibe, M., Soma, T., Miyajima, H., Nagasawa, K., Wada, I., & Sawada, N. (2003) · Experimental Cell Research · doi:10.1016/s0014-4827(03)00354-9 · Cited by 207
Persidsky, Y., Heilman, D., Haorah, J., Zelivyanskaya, M., Persidsky, R., Weber, G. A., Shimokawa, H., Kaibuchi, K., & Ikezu, T. (2006) · Blood · doi:10.1182/blood-2005-11-4721 · Cited by 200
TNF-α knockout and minocycline treatment attenuates blood–brain barrier leakage in MPTP-treated mice
Zhao, C., Ling, Z., Newman, M. B., Bhatia, A., & Carvey, P. M. (2007) · Neurobiology of Disease · doi:10.1016/j.nbd.2006.11.012 · Cited by 183
Behzadian, M. A., Wang, X. L., Windsor, L. J., Ghaly, N., & Caldwell, R. B. (2001) · PubMed · Cited by 179
Progressive Dopamine Neuron Loss in Parkinson's Disease: The Multiple Hit Hypothesis
Carvey, P. M., Punati, A., & Newman, M. B. (2006) · Cell Transplantation · doi:10.3727/000000006783981990 · Cited by 164
Caffeine blocks disruption of blood brain barrier in a rabbit model of Alzheimer's disease
Chen, X., Gawryluk, J. W., Wagener, J. F., Ghribi, O., & Geiger, J. D. (2008) · Journal of Neuroinflammation · doi:10.1186/1742-2094-5-12 · Cited by 152
Self-citationBlood–brain barrier disruption induces in vivo degeneration of nigral dopaminergic neurons
Rite, I., Machado, A., Cano, J., & Venero, J. L. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.04567.x · Cited by 147
Monahan, A. J., Warren, M., & Carvey, P. M. (2008) · Cell Transplantation · doi:10.3727/096368908784423328 · Cited by 126
Changes in vascularization in substantia nigra pars compacta of monkeys rendered parkinsonian
Barcia, C., Bautista‐Hernández, V., Sánchez-Bahíllo, A., Fernández‐Villalba, E., Faucheux, B. A., Poza, M., Barreiro, A. F., Hirsch, É. C., & Herrero, M. T. (2005) · Journal of Neural Transmission · doi:10.1007/s00702-004-0256-2 · Cited by 120
Free radicals in Parkinson's disease
Koutsilieri, E., Scheller, C., Grünblatt, E., Keinosuke, N. A. R. A., Li, J., & Riederer, P. F. (2002) · Journal of Neurology · doi:10.1007/s00415-002-1201-7 · Cited by 117
Rudolphi, K. A., Keil, M., Fastbom, J., & Fredholm, B. B. (1989) · Neuroscience Letters · doi:10.1016/0304-3940(89)90112-2 · Cited by 116
Stimulation of Interleukin‐6 Secretion and Gene Transcription in Primary Astrocytes by Adenosine
Schwaninger, M., Neher, M., Viegas, E., Schneider, A., & Spranger, M. (1997) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1997.69031145.x · Cited by 95
The Effect of Long Term Caffeine Treatment on Hypoxic-Ischemic Brain Damage in the Neonate
Bona, E., Ådén, U., Fredholm, B. B., & Hagberg, H. (1995) · Pediatric Research · doi:10.1203/00006450-199509000-00007 · Cited by 95
Hoane, M., Kaplan, S., & Ellis, A. L. (2006) · Brain Research · doi:10.1016/j.brainres.2006.10.019 · Cited by 85
Francis, J. W., Visger, J. R. V., Markelonis, G. J., & Oh, T. H. (1995) · Neurotoxicology and Teratology · doi:10.1016/0892-0362(94)00048-i · Cited by 79
Sutherland, G. R., Peeling, J., Lesiuk, H. J., Brownstone, R. M., Rydzy, M., Saunders, J. K., & Geiger, J. D. (1991) · Neuroscience · doi:10.1016/0306-4522(91)90157-j · Cited by 78
Self-citationEmerging roles for telomerase in neuronal development and apoptosis
Mattson, M. P., & Klapper, W. (2001) · Journal of Neuroscience Research · doi:10.1002/1097-4547(20010101)63:1 · Cited by 76
Mogi, M., Togari, A., Ogawa, M., Ikeguchi, K., Shizuma, N., Dong-shen, F., Nakano, I., & Nagatsu, T. (1998) · Neuroscience Letters · doi:10.1016/s0304-3940(98)00427-3 · Cited by 69
Tichauer, J. E., Saud, K., & Rommy von Bernhardi, M. (2007) · NeuroImmunoModulation · doi:10.1159/000110642 · Cited by 68
Lorenzl, S., Calingasan, N. Y., Yang, L., Albers, D. S., Shugama, S., Gregorio, J., Krell, H. W., Chirichigno, J. W., JOH, T. H., & Beal, M. F. (2004) · NeuroMolecular Medicine · doi:10.1385/nmm:5:2:119 · Cited by 65
Folcik, V. A., Smith, T., O'Bryant, S., Kawczak, J. A., Zhu, B., Sakurai, H., Kajiwara, A., Staddon, J. M., Glabinski, A. R., Chernosky, A., et al. (1999) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(99)00063-6 · Cited by 56
Experimental developments in movement disorders: update on proposed free radical mechanisms
Przedborski, S., & Jackson-Lewis, V. R. (1998) · Current Opinion in Neurology · doi:10.1097/00019052-199808000-00009 · Cited by 45
Relationship between caffeine intake and Parkinson disease.
Ross, G., Abbott, R., Petrovitch, H., White, L., & Tanner, C. M. (2000) · PubMed · Cited by 42
Impaired Functional Recovery After Stroke in the Stroke-Prone Spontaneously Hypertensive Rat
McGill, J. K., Gallagher, L., Carswell, H. V. O., Irving, E. A., Dominiczak, A. F., & Macrae, I. M. (2004) · Stroke · doi:10.1161/01.str.0000149629.32525.b7 · Cited by 34
Ross (2000) · doi:10.1001/jama.284.11.1378 · Cited by 16
Inflammatory Mechanisms in Parkinson's Disease
Rogers, J., & Kovelowski, C. J. (2003) · Humana Press eBooks · doi:10.1007/978-1-59259-297-5_21 · Cited by 5
Cited by
Sorted by citations
Neurovascular pathways to neurodegeneration in Alzheimer’s disease and other disorders
Zlokovic, B. V. (2011) · Nature Reviews Neuroscience · doi:10.1038/nrn3114 · Cited by 2,969
Blood-Brain Barrier: From Physiology to Disease and Back
Sweeney, M. D., Zhao, Z., Montagne, A., Nelson, A. R., & Zlokovic, B. V. (2019) · Physiological Reviews · doi:10.1152/physrev.00050.2017 · Cited by 2,312
Adenosine receptors as drug targets — what are the challenges?
Chen, J., Eltzschig, H. K., & Fredholm, B. B. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3955 · Cited by 923
Caffeine: Cognitive and Physical Performance Enhancer or Psychoactive Drug?
Cappelletti, S., Daria, P., Sani, G., & Aromatario, M. (2015) · Current Neuropharmacology · doi:10.2174/1570159x13666141210215655 · Cited by 631
“In epidemiological reports, caffeine consumption was associated with a significantly lower risk of developing them [4, 11, 12, 120-122, 124].”
BackgroundAstrocytic modulation of blood brain barrier: perspectives on Parkinson’s disease
Cabezas, R., Ávila, M. F., González, J., El-Bachá, R. D. S., Báez-Jurado, E., García‐Segura, L. M., Jurado-Coronel, J. C., Capani, F., Cardona‐Gómez, G. P., & Barreto, G. E. (2014) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2014.00211 · Cited by 481
Metadata
- Authors
- Chen, X., Lan, X., Roche, I., Liu, R., & Geiger, J. D.
- Affiliations
- University of North Dakota (US)
- Venue
- Journal of Neurochemistry
- Publisher
- Wiley
- Published
- 2008-10-21
- Volume
- 107
- Issue
- 4
- Pages
- 1147-1157
- ISSN
- 0022-3042 (ISSN-L)
- 1471-4159
- PMC
- PMC3692355
- OpenAlex
- W2006684548
- Cited by
- 189
- References
- 71
- Citations by year
- 2026: 7 · 2025: 9 · 2024: 12 · 2023: 18 · 2022: 11 · 2021: 14 · 2020: 13 · 2019: 11 · 2018: 7 · 2017: 9 · 2016: 13 · 2015: 11 · 2014: 10 · 2013: 10 · 2012: 9
- FWCI
- 5.47
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Neurochemistry (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Center for Research Resources (P20RR17699, P20RR017699)
- Topics
- Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
- Keywords
- caffeine, MPTP, blood-brain barrier dysfunction, Parkinson's disease, striatum, tight junction proteins, occludin, ZO-1, dopaminergic neurons, tyrosine hydroxylase, reactive gliosis, astrocytes, microglia, neuroprotection, neurotoxicity
- MeSH terms
- Central Nervous System Stimulants, Analysis of Variance, Animals, Blood-Brain Barrier, Caffeine, Corpus Striatum, Disease Models, Animal, Evans Blue, Gene Expression Regulation, Gliosis, Male, Membrane Proteins, Phosphoproteins, RNA, Messenger, Tyrosine 3-Monooxygenase, MPTP Poisoning, Matrix Metalloproteinase 9, Mice, Occludin, Zonula Occludens-1 Protein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
